Atomo Diagnostics Ltd
ASX:AT1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (45.2), the stock would be worth AU$-0.22 (953% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.3 | AU$0.03 |
0%
|
| Industry Average | 45.2 | AU$-0.22 |
-953%
|
| Country Average | 22.3 | AU$-0.11 |
-520%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| AU |
|
Atomo Diagnostics Ltd
ASX:AT1
|
23.4m AUD | -5.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.9 |
| Median | 22.3 |
| 70th Percentile | 36.3 |
| Max | 5 709.2 |
Other Multiples
Atomo Diagnostics Ltd
Glance View
Atomo Diagnostics Ltd. engages in manufacturing, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-04-16. The firm is engaged in the development and sale of medical devices. Its AtomoRapid is offering rapid diagnostic test (RDT) platform, which provides devices to the global diagnostic market. Its RDT device platforms include Galileo, Pascal, Losev, Newton, Franklin and Elion. The company also offers blood-based rapid diagnostic test (RDT) for screening for human immunodeficiency virus (HIV). Its RDT platform includes various features, such as integrated lancelet, blood collection, buffer delivery and digital display. The company is also engaged in sales of Atomo branded COVID-19 rapid antibody and antigen tests in Australia.
